

CSD/BM/SE/2026-27

Date: 6th August, 2026

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Outcome of Board Meeting

.....

Pursuant to the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that the Board of Directors of the Company, at its meeting held today i.e. August 6, 2026, has considered and approved Un-Audited Financial Results (Standalone and Consolidated) along with review reports of the Statutory Auditors for the quarter ended 30th June, 2026.

Enclosed herewith the following documents:-

1. The Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026 enclosed as **Annexure 1**
2. Limited Review Reports of Statutory Auditors of the Company enclosed as **Annexure 2**
3. News Release of the Company enclosed as **Annexure 3**

Update on patents are available at: <https://www.suven.com/Patentupdates.aspx>

The Board Meeting commenced at 11:30 AM (IST) and concluded at 12:30 PM (IST).

This is for your information and records.

Thanking you.

Yours faithfully,

For **Suven Life Sciences Limited**

K. Sangeetha Laxmi

Company Secretary and Compliance officer

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com



SUVEN LIFE SCIENCES LIMITED

Registered Office: 8-2-334, SDE Serene Chambers, 6th Floor, Road No. 5, Avenue 7, Banjara Hills, 500034, Telangana, India
Tel: 91 40 2354 1142/ 1152 Email: investorservices@suvlen.com Website: www.suvlen.com CIN: L24110TG1989PLCO09713

STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

Rs. In Lakhs

Sl. No.	PARTICULARS	STANDALONE			
		For the Quarter Ended			For the Year ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		Un-Audited	Refer note.7	Un-Audited	Audited
1	Income				
	Revenue from operations	356.58	152.01	186.67	711.47
	Other Income	752.36	677.78	58.90	1,391.05
	Total income	1,108.94	829.79	245.57	2,102.52
2	Expenses				
	a) Cost of materials consumed	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	c) Employee benefits expense	728.18	582.89	597.56	2,414.94
	d) Finance costs	47.61	15.78	-	15.78
	e) Depreciation and amortisation expenses	215.51	158.25	136.84	561.35
	f) R & D Expenses	1,275.60	810.19	518.77	2,797.24
	g) Other Expenses	453.95	379.41	470.27	1,799.49
	Total expenses	2,720.85	1,946.52	1,723.44	7,588.80
3	Profit before exceptional items & Tax (1-2)	(1,611.91)	(1,116.73)	(1,477.87)	(5,486.28)
4	Exceptional Items	-	-	-	-
5	Profit/(Loss) before Tax (3-4)	(1,611.91)	(1,116.73)	(1,477.87)	(5,486.28)
6	Tax Expenses				
	a) Current tax	-	-	-	-
	b) Deferred tax	-	-	-	-
	c) Tax of earlier years	-	-	-	-
7	Net Profit/ (Loss) for the period/year(5-6)	(1,611.91)	(1,116.73)	(1,477.87)	(5,486.28)
8	Other Comprehensive Income				
8.a	(i) Items that will not be reclassified to profit or loss	(5.55)	(22.45)	(1.50)	(22.19)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	(5.55)	(22.45)	(1.50)	(22.19)
9	Total Comprehensive Income for the period (7+8)	(1,617.46)	(1,139.18)	(1,479.37)	(5,508.47)
10	Paid-up equity share capital	2,639.93	2,637.20	2,180.74	2,637.20
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	-	-	-	147,699.51
12	Earning Per Share (EPS)				
	(Face value of Rs.1/- each)				
	a) Basic	(0.61)	(0.50)	(0.68)	(2.41)
	b) Diluted	(0.61)	(0.50)	(0.68)	(2.41)
		(not annualised)	(not annualised)	(not annualised)	(annualised)



Rs. In Lakhs					
		CONSOLIDATED			
Sl. No.	PARTICULARS	For the Quarter Ended			For the Year ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		Un-Audited	Refer note. 7	Un-Audited	Audited
1	Income				
	Revenue from operations	356.58	152.01	186.67	711.47
	Other Income	752.36	677.78	59.98	1,393.01
	Total income	1,108.94	829.79	246.65	2,104.48
2	Expenses				
	a) Cost of materials consumed	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	c) Employee benefits expense	728.18	582.89	597.56	2,414.94
	d) Finance costs	47.61	15.78	-	15.78
	e) Depreciation and amortisation expense	215.51	158.25	136.84	561.35
	f) R & D Expenses	12,383.10	4,233.12	4,148.84	24,818.81
	g) Other Expenses	495.57	399.30	515.10	1,928.01
	Total expenses	13,869.97	5,389.34	5,398.34	29,738.89
3	Profit before exceptional items, Tax (1-2)	(12,761.03)	(4,559.55)	(5,151.69)	(27,634.41)
4	Exceptional Items	-	-	-	-
5	Profit/(Loss) before Tax (3-4)	(12,761.03)	(4,559.55)	(5,151.69)	(27,634.41)
6	Tax Expenses				
	a) Current tax	-	-	-	-
	b) Deferred tax	-	-	-	-
	c) Tax of earlier years	-	-	-	-
7	Net Profit/ (Loss) for the period/year(5-6)	(12,761.03)	(4,559.55)	(5,151.69)	(27,634.41)
8	Other Comprehensive Income				
8.a	(i) Items that will not be reclassified to profit or loss	(5.55)	(22.45)	(1.50)	(22.19)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	1.95	(24.21)	(3.62)	(96.20)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	(3.60)	(46.66)	(5.12)	(118.39)
9	Total Comprehensive Income for the period (7+ 8)	(12,764.63)	(4,606.21)	(5,156.81)	(27,752.80)
10	Paid-up equity share capital	2,639.93	2,637.20	2,180.74	2,637.20
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	-	-	-	56,502.76
12	Earning Per Share (EPS) (Face value of Rs.1/- each)				
	a) Basic	(4.84)	(2.02)	(2.36)	(12.13)
	b) Diluted	(4.84)	(2.02)	(2.36)	(12.13)
		(not annualised)	(not annualised)	(not annualised)	(annualised)



NOTES:-

- 1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 06, 2026. The financial results for the quarter ended June 30, 2026 has been reviewed by our statutory auditors and issued unmodified reports thereon.
- 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc.
- 4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
- 5.1) The Company implemented SLSL Employee Stock Option Scheme 2020 ("ESOP") for eligible employees, 1,33,200 stock options were granted on May 13, 2026 by the Nomination & Remuneration Committee.
- 5.2) ESOP: for the quarter ended June 30, 2026, the Company has recognized an employee benefit expense (EBP) of Rs. 145.54 lakhs in accordance with Ind AS 102 – Share-based Payment.
- 5.3) During the quarter ended June 30, 2026, the Company has allotted 2,71,970 equity shares of Rs.1 each, pursuant to the exercise of stock options by the employees of the company under Employee Stock Options Scheme 2020.
- 6) Preferential Issue: The Board of Directors of the Company has approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Subsequently, shareholders of the Company approved the issue of convertible warrants in their meeting held on 05th June, 2025.

Each warrant is convertible into one equity share of face value ₹1 at an exercise price of ₹134 per share, within a period of 18 months from the date of allotment.

As on 30 June 2026, the company has received the entire amount of Rs.85,764.02 lakhs from the warrant holders, out of which an amount of Rs.9,331.49 lakhs was received during the quarter in respect of 1,85,70,133 warrants, for which allotment is pending as on reporting date.

Summary of Utilisation of Proceeds of Preferential issue as on 30.06.2026

Particulars	Amount Rs. in Lakhs
Amount Received through Preferential Issue	85,764.02
Less: Amount Utilised	40,950.29
Balance Amount	44,813.73

- 7) The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to third quarter of the financial year.

Place : Hyderabad
Date: August 06, 2026



For SUVEN LIFE SCIENCES LIMITED

VENKAT JASTI
Chairman & MD
DIN: 00278028

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF
INTERIM UNAUDITED STANDALONE FINANCIAL RESULTS**

**TO
THE BOARD OF DIRECTORS OF
SUVEN LIFE SCIENCES LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SUVEN LIFE SCIENCES LIMITED**, having registered office at 6th Floor, SDE Serene Chambers, Road No 5, Banjara Hills, Hyderabad - 500034, Telangana, for the quarter ended June 30th, 2026 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation) as amended.

2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KARVY & CO
Chartered Accountants
(Firm Regn.No.001757S)

AJAYKUMAR KOSARAJU
Partner

M.No. 021989

UDIN: 2602198902YZNR7241



Place: Hyderabad
Date : 06-08-2026

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
UNAUDITED CONSOLIDATED FINANCIAL RESULTS**

To
The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **SUVEN LIFE SCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Regulation")


2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind-AS 34") 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the Results of the following Entities:

Name of the Company	Relationship
Suven Life Sciences Limited	Parent
Suven Neuro Sciences Inc	Wholly Owned Subsidiary



06-08-2026

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below nothing has come to our attention that causes us to believe that the accompanying Statement. prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of the subsidiary included in the unaudited consolidated financial results, whose interim financial information reflect total revenues Nil, and total net loss after tax of Rs.(11,149.11) lakhs for the quarter ended June 30, 2026, and total comprehensive income of Rs.(11,147.17) Lakhs for the quarter ended June 30, 2026 as considered in the Statement. This interim financial information has been reviewed by other auditor whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the reports of the other auditor.

Our conclusion on the statement is not modified in respect of the above matters.

For KARVY & CO.,
Chartered Accountants
(Firm Registration No .001757S)



AJAYKUMAR KOSARAJU

Partner

M.No. 021989

UDIN:26021989XXFC ZJ8731

Place: Hyderabad

Date: 06-08-2025

06-08-2026

News Release

HYDERABAD, INDIA (06 August 2026) - SUVEN Life Sciences Limited ("Suven") today announced unaudited financial results for the quarter ended 30 June 2026. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 06 August 2026 at Hyderabad.

CONSOLIDATED STATEMENT OF OPERATIONS

INR Million, except EPS

	Quarter ended			Year ended
	30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
Revenue	110.89	82.98	24.67	210.45
R&D and Operational expenses	1,360.69	521.52	526.15	2,916.17
Depreciation and Amortisation	21.55	15.83	13.68	56.14
Finance cost	4.76	1.58	-	1.58
Total expenses	1,387.00	538.93	539.83	2,973.89
Exceptional items (insurance claim received)	-	-	-	-
Tax	-	-	-	-
Profit/(Loss) After Tax for the period/year	(1,276.10)	(455.96)	(515.17)	(2,763.44)
Other comprehensive income	(0.36)	(4.67)	(0.51)	(11.84)
Total comprehensive income	(1,276.46)	(460.62)	(515.68)	(2,775.28)
Paid up equity capital	263.99	263.72	218.07	263.72
Earnings per share of Rs.1 each (EPS)	(4.84)	(2.02)	(2.36)	(12.13)

(a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.

(b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.

(c) Clinical development pipeline:

- SUVN-502 (Masupirdine) – Achieves 95% Enrollment milestone in Global Phase 3 Trial for Agitation in Alzheimer's Dementia. The completion of patient enrolment by end of September 2026 and last patient last visit will be in quarter 1, 2027 calendar year enabling progression towards database lock and reporting of results potentially in Q2, 2027 calendar year.
- SUVN-G3031 (Samelisant) – Global Phase 3 clinical trial initiated for treatment of EDS in Narcolepsy in April 2026.
- SUVN-911 (Ropanicant) – Successfully completed Phase 2 b clinical trial evaluating the efficacy and safety of Ropanicant in Major Depressive Disorder (MDD).
- SUVN-D4010 (Usmarapride) – Phase 2 PoC (proof of concept) study design being finalized for a cognitive impairment in psychiatric disorder.
- SUVN-I6107 – Phase 1 study for establishing safety and pharmacokinetics completed and preparing for Phase 2 clinical study.

[For more information on Suven please visit our Web site at http://www.suven.com](http://www.suven.com)

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com